Hiroshi Yukitake
Fujisawa, 2518555, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
AAV9-mediated NGLY1 gene replacement suppresses non-epileptic convulsions in Ngly1-/- rats.
Journal: Biochemical and biophysical research communications
Published: August 26, 2025
Application of human-derived samples in preclinical research
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: September 01, 2024
Elimination of the extra chromosome of Dup15q syndrome iPSCs for cellular and molecular investigation.
Journal: European journal of cell biology
Published: April 17, 2024
Intranasal oxytocin suppresses seizure-like behaviors in a mouse model of NGLY1 deficiency.
Journal: Communications biology
Published: December 05, 2023
Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals.
Journal: Journal of sleep research
Published: November 10, 2022
Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 22, 2022
Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant Orexin 2 Receptor Agonist.
Journal: ACS medicinal chemistry letters
Published: November 08, 2021
TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
Journal: Pharmacology, biochemistry, and behavior
Published: September 11, 2019
Macrophage Migration Inhibitory Factor as an Emerging Drug Target to Regulate Antioxidant Response Element System.
Journal: Oxidative medicine and cellular longevity
Published: August 25, 2016
BTZO-2, an antioxidant response element-activator, provides protection against lethal endotoxic shock in mice.
Journal: European journal of pharmacology
Published: July 27, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026